Why the study?
Does olmesartan improve blood pressure reductions and 24-hour control compared to other ARBs in patients requiring antihypertensive therapy?
Does olmesartan improve blood pressure reductions and 24-hour control compared to other ARBs in patients requiring antihypertensive therapy?
This review suggests that olmesartan may offer superior blood pressure lowering efficacy compared to standard doses of other ARBs.
Hypothesis-generating for olmesartan preference among ARBs; prospective trials needed before clinical adoption.
A range of angiotensin II receptor blockers (ARB) is available, and analyses suggest there are differences between agents in terms of antihypertensive efficacy and 24-hour blood pressure control.This review assesses the data comparing olmesartan with other ARBs in terms of blood pressure reductions, goal achievement, 24-hour control and speed of onset. Olmesartan seems to have a more favourable efficacy profile relative to standard doses of the ARBs used in comparative studies; results consistent with the high degree of blockade of the angiotensin II type 1 receptor for olmesartan.Taken together, there might be differences between ARBs regarding their blood pressure lowering efficacy, and these results may provide further support of the benefits of olmesartan therapy since choice of an effective agent is crucial in antihypertensive therapy.
No takes yet. Share an insight, caveat, or question.
Redón et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: